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ABSTRACT
BACKGROUND Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether
use of extended-duration primary thromboprophylaxis can prevent such events is unknown.
OBJECTIVES The purpose of this study was to evaluate whether extended-duration rivaroxaban reduces the risk of
venous and arterial fatal and major thromboembolic events without significantly increasing major bleeding in acutely ill
medical patients after discharge.
METHODS MARINER (A Study of Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital
Discharge Patients) studied acutely ill medical patients with additional risk factors for venous thromboembolism (VTE).
Medically ill patients with a baseline creatinine clearance $50 ml/min were randomized in a double-blind fashion to
rivaroxaban 10 mg or placebo daily at hospital discharge for 45 days. Exploratory efficacy analyses were performed with
the intent-to-treat population including all data through day 45. Time-to-event curves were calculated using the Kaplan-
Meier method. A blinded independent committee adjudicated all clinical events.
RESULTS In total, 4,909 patients were assigned to rivaroxaban and 4,913 patients to placebo. The mean age was 67.8
years, 55.5% were men, mean baseline creatinine clearance was 87.8 ml/min, and mean duration of hospitalization was
6.7 days. The pre-specified composite efficacy endpoint (symptomatic VTE, myocardial infarction, nonhemorrhagic
stroke, and cardiovascular death) occurred in 1.28% and 1.77% of patients in the rivaroxaban and placebo groups,
respectively (hazard ratio: 0.72; 95% confidence interval: 0.52 to 1.00; p ¼ 0.049), whereas major bleeding occurred in
0.27% and 0.18% of patients in the rivaroxaban and placebo groups, respectively (hazard ratio: 1.44; 95% confidence
interval: 0.62 to 3.37; p ¼ 0.398).
CONCLUSIONS Extended-duration rivaroxaban in hospitalized medically ill patients resulted in a 28% reduction
in fatal and major thromboembolic events without a significant increase in major bleeding. (A Study of
Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients [MARINER];
NCT02111564) (J Am Coll Cardiol 2020;75:3140–7) © 2020 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
ISSN 0735-1097 https://doi.org/10.1016/j.jacc.2020.04.071
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A large proportion of the approximately 8million acute medically ill patients eachyear in the United States are at risk for
venous thromboembolism (VTE) (1). Hospitalization
is considered the single most important risk factor
for developing these events (2), and the risk of VTE
continues beyond hospitalization, especially within
the first 6 weeks after discharge (3). Although the
relationship between VTE and atherothrombosis/
arterial thromboembolism has been known for some
time due to the shared mechanisms of inflammation,
hypercoagulability, and endothelial injury inherent
to both disease processes and due to common
patient-level risk factors, such as obesity, dyslipide-
mia, and tobacco use (4,5), it has only recently been
appreciated that medically ill patients are also at
increased risk of arterial thromboembolic events in
the post-hospital discharge period (6,7). Retrospec-
tive data also reveal that extended duration of a pro-
phylactic dose of a direct oral anticoagulant in
medically ill patients may reduce the risk of fatal
and major arterial thromboembolism by 30% to 50%
(6,7).
The previously reported MARINER trial (A Study of
Rivaroxaban [JNJ-39039039] on the Venous Throm-
boembolic Risk in Post-Hospital Discharge Patients)
(NCT02111564) (8), randomized medically ill patients
with additional risk factors for VTE to extended-
duration rivaroxaban (10 mg once daily for 45 days
or 7.5 mg once daily for those with a creatinine
clearance between 30 and 50 ml/min) or placebo after
excluding those at high risk of bleeding.
Although the trial did not demonstrate a
reduction in the primary endpoint of symp-
tomatic VTE and VTE-related death, key
secondary efficacy endpoints revealed a 56%
reduction in symptomatic VTE and a 27%
reduction in symptomatic VTE and all-cause
mortality. The lower 7.5 mg dose of rivarox-
aban used in patients with moderate renal
insufficiency was found to be ineffective (8), unlike
the dose of 10 mg, which had previously been
demonstrated to be effective in the MAGELLAN
(Venous Thromboembolic Event [VTE] Prophylaxis in
Medically Ill Patients; NCT00571649) study of
extended thromboprophylaxis in medically ill pa-
tients (9). A pre-specified secondary endpoint of the
trial was fatal and major venous and arterial throm-
boembolic events (8). Therefore, this exploratory
analysis focused on whether rivaroxaban could
reduce the incidence of fatal and major thromboem-
bolic events in patients treated with 10 mg daily of
rivaroxaban compared with placebo when given to
acutely ill medical patients at the time of discharge
for 45 days.
METHODS
STUDY DESIGN. The MARINER protocol and study
results have been reported previously (8,10). The
protocol was approved by local ethics committees,
and all subjects provided written informed consent.
Briefly, MARINER was a multicenter, prospective,
randomized, double-blind, placebo-controlled,
SEE PAGE 3148
AB BR E V I A T I O N S
AND ACRONYM S
CI = confidence interval
CrCl = creatinine clearance
HR = hazard ratio
MI = myocardial infarction
VTE = venous
thromboembolism
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event-driven study that evaluated rivaroxaban
(10 mg daily in patients with creatinine clearance
[CrCl] $50 ml/min or 7.5 mg daily with CrCl 30
to <50 ml/min at baseline) versus placebo for 45 days
beyond hospital discharge to prevent symptomatic
VTE and VTE-related death in acutely ill medical pa-
tients. Eligible patients were 40 years of age or older,
were hospitalized for at least 3 and no more than 10
consecutive days prior to randomization for a specific
acute medical illness, and had other risk factors for
VTE. Other VTE risk factors were demonstrated by a
total modified IMPROVE (International Medical Pre-
vention Registry on Venous Thromboembolism) VTE
risk score of $4 or VTE risk score of 2 or 3 with
D-dimer >2 the upper limit of normal. Patients
received thromboprophylaxis during the index hos-
pitalization with low-molecular-weight heparin or
unfractionated heparin. Patients with an increased
risk of bleeding were excluded from the study. The
primary hypothesis was that rivaroxaban was supe-
rior to placebo for the prevention of the composite of
symptomatic VTE (lower extremity deep vein
thrombosis and nonfatal pulmonary embolism [PE])
and VTE-related death (death due to PE or death in
which PE could not be ruled out). The primary hy-
pothesis of this exploratory analysis was that rivar-
oxaban was superior to placebo for the prevention of
the pre-specified composite of symptomatic VTE,
myocardial infarction (MI), nonhemorrhagic stroke,
and cardiovascular (CV) death in the stratum of pa-
tients with a baseline CrCl $50 ml/min receiving the
10 mg dose of rivaroxaban.
STATISTICAL METHODS. The point estimate for the
hazard ratio (HR) and corresponding 95% confidence
interval (CI) for the 10 mg rivaroxaban dose versus
placebo were provided based on the Cox proportional
hazards model. Patients were analyzed according to
the treatment group they were randomized to,
regardless of the actual treatment received. All sta-
tistical tests were interpreted at a nominal (without
adjustment for multiplicity) 2-sided significance level
of 0.05, and all CIs at a nominal 2-sided level of 95%.
The Kaplan-Meier method was used to summarize the
time-to-event analyses.
EFFICACY AND SAFETY OUTCOMES. The efficacy
outcome of the composite of symptomatic VTE,
MI, nonhemorrhagic stroke, and CV death was a
pre-specified secondary endpoint, and individual
outcomes were verified by objective testing and
autopsy reports, where available using standardized
definitions (8). The principal safety outcome of major
bleeding was based on the International Society on
Thrombosis and Haemostasis bleeding criteria and
included fatal bleeding, bleeding into a critical organ,
or bleeding that led to a drop of $2 g/dl of hemoglobin
or a transfusion of 2 U or more of blood. Bleeding
events were analyzed based on time from randomiza-
tion to the first occurrence. All endpoints were adju-
dicated by a blinded clinical events committee.
RESULTS
BASELINE CHARACTERISTICS. A total of 4,909 pa-
tients were assigned to the rivaroxaban 10 mg group
(baseline CrCl $50 ml/min) and 4,913 patients to
matching placebo and are included in the intent-to-
treat (ITT) population. The ITT analysis set included
all randomized patients who had valid informed
consent. Baseline characteristics were well balanced
between treatment groups (Table 1). The mean age of
this population was 67.8 years, 55.5% were men, and
96.5% were white. The most frequently reported







Mean age, yrs 67.8 67.7
White race 96.3 96.7
Mean BMI, kg/m2 29.5 29.3
Reason for hospitalization
Heart failure 37.4 37.0
Respiratory insufficiency or exacerbation of chronic
obstructive pulmonary disease
27.6 28.0
Ischemic stroke 15.5 15.7
Infectious disease 17.9 17.7
Inflammatory disease 1.5 1.7
Mean duration of index hospitalization, days 6.7 6.7
D-dimer >2 upper limit of normal during the index
hospitalization
68.7 68.7
Mean baseline CrCl 87.9 87.8
Baseline aspirin 51.9 49.1
Current or former smoker 48.2 48.3
Baseline statin 41.9 41.4
Baseline U.S.-approved thromboprophylaxis 71.2 71.5
History of hypertension 78.2 78.8
History of diabetes 29.5 27.9
History of heart failure 47.9 47.5
History of coronary artery disease 32.1 31.1
History of hyperlipidemia 20.5 19.6
History of cancer 8.0 8.7




Values are % or mean (where indicated). Note: intention-to-treat (ITT): all randomized patients
who had valid signed informed consent. U.S.-approved thromboprophylaxis includes enoxaparin,
dalteparin, and heparin. Patients who have both U.S.-approved and other baseline use of
thromboprophylaxis are included in the U.S.-approved thromboprophylaxis category.
BMI ¼ body mass index; CrCl ¼ creatine clearance; IMPROVE VTE ¼ International Medical
Prevention Registry on Venous Thromboembolism venous thromboembolism model.
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admitting diagnosis for patients overall was heart
failure with reduced ejection fraction #45% (37.2%)
and the mean duration of hospitalization was 6.7 
2.4 days. Overall, 52.0% of patients had a baseline
CrCl level $80 ml/min and 47.9% had a baseline CrCl
50 to <80 ml/min with a mean baseline creatine
clearance of 87.8 ml/min. At baseline, aspirin was
used in 51.9% of patients; a statin was used by 41.7%.
A history of reduced or preserved ejection fraction
heart failure (47.7%), coronary artery disease (31.6%),
diabetes (28.7%), and hyperlipidemia (20.0%) were
also common in the population. A history of cancer
was reported by 8.3% of patients, while patients with
active cancer undergoing chemotherapy were
excluded. Total modified IMPROVE VTE risk factor
scores of 2, 3, and $4 were reported for 35.8%, 28.4%,
and 35.8% of patients, respectively.
EFFICACY AND SAFETY OUTCOMES. The composite
endpoint of symptomatic VTE, MI, nonhemorrhagic
stroke, and CV death occurred in 1.28% of patients
randomized to rivaroxaban and in 1.77% of those on
placebo (HR: 0.72; 95% CI: 0.52 to 1.00; p ¼ 0.049)
(Table 2). All incidence of the components of the
composite endpoint, except MI, numerically tended
to favor rivaroxaban. Symptomatic lower-extremity
deep vein thrombosis and symptomatic nonfatal PE
showed greater risk reduction with rivaroxaban with
a relative risk reduction of 80% (HR: 0.20; 95% CI:
0.04 to 0.91) and 62% (HR: 0.36; 95% CI: 0.12 to 1.14),
respectively (Table 2). Kaplan-Meier curves for the
composite of symptomatic VTE, MI, nonhemorrhagic
stroke, and CV death are presented in the
Central Illustration.
The bleeding analysis used the safety population,
which for the 10 mg dose included 4,890 in both the
rivaroxaban and placebo groups for a total of 9,780
patients. Major bleeding occurred in 13 (0.27%) and 9
(0.18%) patients in the rivaroxaban and placebo
groups, respectively (HR: 1.44; 95% CI: 0.62 to 3.37;
p ¼ 0.398) (Table 3). When evaluated by type of
major bleeding, a greater proportion of patients
receiving 10 mg rivaroxaban than placebo had major
bleeding events with a fall in hemoglobin of $2 g/dl
(0.22% and 0.12%, respectively) and transfusion
of >2 U of packed red blood cells (or whole blood)
than patients in the placebo group (0.16% and 0.06%,
respectively). There were 2 critical site bleeds in each
group, and 2 fatal bleeds in the rivaroxaban group. A
Kaplan-Meier analysis of the timing of major bleeding
occurrence is shown in the Central Illustration.
DISCUSSION
This analysis demonstrates that compared with pla-
cebo, extended-duration thromboprophylaxis with
low-dose rivaroxaban (10 mg daily) started after
hospital discharge leads to a significant 28% reduc-
tion in the combined risk of fatal and major throm-
boembolic events without a significant increase in
major bleeding in hospitalized medically ill patients.
This benefit appears to begin after the first week of
treatment and continues until the end of study at
45 days. There was a 0.49% absolute risk reduction of
efficacy events and a 0.09% absolute increase in the
risk of major bleeding, suggesting a net clinical
benefit.
A meta-analysis of arterial thrombosis (including
MI and ischemic stroke) of older studies involving
w11,000 medically ill inpatients receiving heparin-
based prophylaxis did not find a reduction of these
events compared with control subjects (odds ratio:
1.95; 95% confidence interval: 0.89 to 4.27) (11). The
TABLE 2 Time to First Occurrence of Composite Outcome and Components (ITT)
Endpoint Rivaroxaban 10 mg Placebo
Rivaroxaban 10 mg vs. Placebo
HR (95% CI)* p Value†
Composite of symptomatic VTE (DVT and nonfatal PE),
MI, nonhemorrhagic stroke, CV death
63/4,909 (1.28) 87/4,913 (1.77) 0.72 (0.52–1.00) 0.049
Symptomatic lower extremity DVT 2/4,909 (0.04) 10/4,913 (0.20) 0.20 (0.04–0.91) —
Symptomatic nonfatal PE 4/4,909 (0.08) 11/4,913 (0.22) 0.36 (0.12–1.14) —
MI 13/4,909 (0.26) 8/4,913 (0.16) 1.62 (0.67–3.92) —
Nonhemorrhagic stroke 13/4,909 (0.26) 24/4,913 (0.49) 0.54 (0.28–1.06) —
CV death 39/4,909 (0.79) 42/4,913 (0.85) 0.93 (0.60–1.44) —
Values are n/N (%) unless otherwise indicated. CV death includes VTE-related death. All events were adjudicated by the clinical event committee. Intention-to-treat (ITT): all
randomized patients who had valid signed informed consent. *HRs (95% CIs) are from Cox proportional hazards model with treatment as the only covariate. †The p value (2-
sided) for superiority of rivaroxaban versus placebo from Cox proportional hazards model.
CI ¼ confidence interval; CV ¼ cardiovascular; DVT ¼ deep vein thrombosis; HR ¼ hazard ratio; MI ¼ myocardial infarction; PE ¼ pulmonary embolism; VTE ¼ venous
thromboembolism.
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Spyropoulos, A.C. et al. J Am Coll Cardiol. 2020;75(25):3140–7.
(A) Time to first occurrence of composite: venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death up to day 45 (rivaroxaban
10 mg daily vs. placebo; intention to treat). Includes all data from randomization to day 45 (inclusive). Patients who do not have events are censored on the minimum of
last visit before or on death or day 45. (B) Time to first occurrence of major bleeding on-treatment (rivaroxaban 10 mg daily vs. placebo; safety population).
On-treatment includes all data from randomization to 2 days after the last dose of the study drug (inclusive). Subjects who do not have events are censored on the
minimum of last visit before or on death, or last dose þ2 days. CI ¼ confidence interval; HR ¼ hazard ratio.
Spyropoulos et al. J A C C V O L . 7 5 , N O . 2 5 , 2 0 2 0
Rivaroxaban for Medically Ill Patients J U N E 3 0 , 2 0 2 0 : 3 1 4 0 – 7
3144
authors concluded that arterial thrombotic events
appeared to be under-reported in trials of venous
thromboprophylaxis, and they recommended sys-
tematic monitoring of such events in future trials. In
the MARINER study, data on arterial events were
captured using a standardized data collection form,
and all suspected events were centrally adjudicated
using pre-specified criteria. Although exploratory,
our analysis suggests that extended thromboprophy-
laxis with rivaroxaban in medically ill patients may
lead to reductions in arterial thromboembolic events
(primarily ischemic stroke) as well as a reduction in
symptomatic VTE. Such a finding is in line with the
results of the APEX trial (12), which in post hoc ana-
lyses revealed a w30% reduction in fatal and irre-
versible ischemic events (including PE, MI, nonfatal
ischemic stroke, or CV death) without an increase in
fatal or intracranial hemorrhage, and a w50% reduc-
tion in ischemic stroke with betrixaban compared
with placebo (6,7). A recent pooled analysis of both
the MARINER and MAGELLAN trials of extended
thromboprophylaxis with the 10 mg dose of rivarox-
aban also revealed a significant 22% reduction in all-
cause mortality and major thromboembolic events,
including symptomatic VTE, MI, and nonhemorrhagic
stroke (1.80% vs. 2.31%; HR: 0.78; 95% CI: 0.63 to
0.97; p ¼ 0.024), without an increase in critical site or
fatal bleeding (13).
The association between VTE and arterial throm-
boembolic disease has been well-established (5,14).
Underlying common mechanisms of both VTE and
arterial thromboembolism suggest that primary
thromboprophylaxis using an established anticoagu-
lant regimen, possibly against a background of anti-
platelet therapy and given for a sufficient duration,
can be effective in reducing both types of events. An
analysis of MARINER data in the subset of patients
receiving rivaroxaban plus aspirin, although not
randomized for aspirin use and hypothesis gener-
ating, suggested greater efficacy with rivaroxaban
plus aspirin in reducing symptomatic VTE and VTE-
related death (15). In the COMPASS (Rivaroxaban for
the Prevention of Major Cardiovascular Events in
Coronary or Peripheral Artery Disease; NCT01776424)
trial, a very large study that compared 2.5 mg twice
daily of rivaroxaban plus 100 mg aspirin daily with
100 mg aspirin daily alone in patients with chronic
coronary artery disease or peripheral artery disease,
rivaroxaban plus aspirin significantly reduced the
incidence of CV death, stroke, and MI by 24% (16).
This dose of rivaroxaban would be predicted to pro-
duce trough levels similar to those achieved with
10 mg once daily (17,18); this finding was supported
by data from the MARINER pharmacokinetic sub-
study in patients receiving the 10 mg dose (9).
Our findings may have important implications for
the population of medically ill patients now that
rivaroxaban is approved for extended post-hospital
discharge thromboprophylaxis in at-risk medically
ill patients in the United States. A previous benefit/
risk assessment of a low-bleed risk subpopulation of
the MAGELLAN trial revealed that extended throm-
boprophylaxis with the 10 mg dose of rivaroxaban
would lead to 21 fewer fatal and major thromboem-
bolic events per 10,000 patients at the expense of 9
more critical site or fatal bleeds, with a number
needed to treat of 481 and number needed to harm of
1,061 (19). In the large population of at-risk medically
ill patients each year, this strategy would have the
potential to prevent 12,000 fatal and major throm-
boembolic events annually at the cost of one-fourth
to one-half that number of major or fatal bleeds (19).
STUDY LIMITATIONS. Limitations of this study
include its exploratory nature, because the MARINER
study failed to meet its primary efficacy endpoint. We
cannot exclude potential under-reporting of arterial
thromboembolic events as the trial was powered to
assess the risk of VTE, although this is unlikely
because a standardized case report form was used
with careful study oversight of outcomes and central
adjudication of all of these events. In addition, the
composite endpoint was driven primarily by a
reduction in symptomatic VTE and ischemic stroke.
Although event rates may be considered low (<2.0%),
the time-to-event curves suggest that events
continued to accumulate after the study period of
45 days such that we cannot exclude the possibility
TABLE 3 Time to First Occurrence of Major Bleeding Event, On-Treatment
(Safety Analysis Set)
Endpoint Rivaroxaban 10 mg Placebo
Rivaroxaban 10 mg
vs. Placebo
HR (95% CI)* p Value†
ISTH major bleeding 13/4,890 (0.27) 9/4,890 (0.18) 1.44 (0.62–3.37) 0.398
Fall in hemoglobin
of $2 g/dl
11/4,890 (0.22) 6/4,890 (0.12) 1.83 (0.68–4.95) —
Transfusion of $2 U
of packed red blood
cells or whole blood
8/4,890 (0.16) 3/4,890 (0.06) 2.66 (0.71–10.04) —
Critical site 2/4,890 (0.04) 2/4,890 (0.04) 1.00 (0.14–7.10) —
Fatal outcome 2/4,890 (0.04) 0/4,890 NA NA
Values are n/N (%) unless otherwise indicated. All adjudicated by the clinical event committee. Safety analysis
set: all intention-to-treat patients who take at least 1 dose of study drug. *HRs (95% CIs) are from Cox pro-
portional hazards model with treatment as the only covariate. †p value (2-sided) for superiority of rivaroxaban vs.
placebo from Cox proportional hazards model.
ISTH ¼ International Society on Thrombosis and Haemostasis; NA ¼ not applicable; other abbreviations as in
Table 2.
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that rivaroxaban continues to reduce these events
over a longer period of time. Our study also excluded
subjects with moderate renal insufficiency because
the reduced dose chosen (7.5 mg) was deemed inad-
equate. However, a recent study has demonstrated
efficacy in this population with 10 mg daily of rivar-
oxaban with a favorable benefit risk profile (9). As
approximately 50% of our study population had
baseline aspirin use, an important antithrombotic
synergy between prophylactic dose rivaroxaban and
antiplatelet therapy cannot be excluded, and there
are mechanistic implications of such a synergistic
antithrombotic strategy that may lead to reductions
in CV outcomes (15,16).
CONCLUSIONS
Our analysis suggests that in at-risk medically ill pa-
tients who are discharged from the hospital,
extended-duration rivaroxaban at the 10 mg daily
dose leads to a significant risk reduction in a com-
posite of fatal and major thromboembolic events—
including symptomatic VTE, MI, nonhemorrhagic
stroke, and CV death—without a significant increase
in major bleeding, compared with placebo. These data
suggest that in properly selected patients at risk for
VTE and at low risk for bleeding, that extended-
duration rivaroxaban at 10 mg has a favorable
benefit risk profile.
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